Related Experiment Video
Updated: May 5, 2026

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
Identification of Candidate Inhibitors to SARS-CoV-2's Enzymes and Potential Disruptors of Its Structural Proteins'
Ali Mohammadian1, Mahdieh Jadaliha2, Aylar Imanpour3
1Faculty of Biotechnology, Amol University of Special Modern Technologies, Amol, Iran.
Background:
Many studies have assessed the possible inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, experiences like that from human immunodeficiency virus have taught us that a multidrug approach will reduce the chance of viral resistance.
Materials And Methods:
Here, we screened 2371 Food and Drug Administration-approved drugs for possible inhibition of nonstructural proteins of SARS-CoV-2 and expanded the work to include ligands that might interfere with the roles of structural proteins. Three different algorithms were used and suggested hits obtained using qVina were verified using Autodock Vina and leDock software.
Results:
Our results suggest direct-acting antivirals against hepatitis C might be efficient against SARS-CoV-2.
Conclusions:
Drug repurposing is a promising approach for the rapid identification of potential treatments for emerging diseases such as coronavirus disease.
Related Concept Videos
Enzyme Inhibition
Protein-protein Interfaces
Inhibitors of Viral Protein Synthesis

